To investigate the diversity of the T cell repertoire involved in human T lymphotropic virus type I (HTLV-I) infections, peripheral blood T cell subsets were analyzed by using a PCR-based assay that permits determination of complementarity-determining region 3 (CDR3) length variation in TCR Vβ transcripts. In two of four asymptomatic HTLV-I carriers and in four of five patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), mono- or oligoclonal expansions were detected in the CD4+ T cell subset. In one patient with adult T cell leukemia, a specific clone bearing Vβ7 was detected in the CD4+ T cell subset. In contrast, clonal expansion was not observed in the CD4 T cell subsets of three individuals with asymptomatic HTLV-II infection or in our previous studies of a large number of uninfected individuals. Oligoclonal expansions in the CD8+ T cell subset were detected in all subjects, including the patient with adult T cell leukemia. No differences in the number of expanded clones were noted between asymptomatic carriers and in patients with HAM/TSP and there was no obvious restriction in the TCR V region usage. Direct sequencing revealed no significant bias in the CDR3 motifs utilized by the predominant clones. This report is the first direct demonstration of clonal expansions within fractionated T cell subsets (CD4+ and CD8+) in HTLV-I infections and suggests that 1) clonal expansion of CD4+ T lymphocytes likely occurs as a direct result of infection and 2) polyclonal CD8+ T cell expansion occurs frequently and independently of disease association.

Human T cell lymphotropic virus type I (HTLV-I)3 is endemic in a number of established geographic areas. While the vast majority of infected individuals in these areas are asymptomatic carriers (ACs), infection is associated with adult T cell leukemia (ATL), a fatal CD4+ T-lymphoproliferative disorder (1), and a nonfatal neurological disorder, HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (2). In addition, a number of reports have described evidence of inflammatory involvement outside of the central nervous system in patients both with and without HAM/TSP. The associated clinical conditions include lymphocytic alveolitis, uveitis, Sjögren’s syndrome, arthropathy, and polymyositis (2, 3), and the interactions between infected cells and responding T cells in the various affected compartment(s) are considered to be key factors in disease development (4, 5). In all HTLV-I-infected individuals a relative and preferential tropism of HTLV-I for CD4+ T cells has been consistently demonstrated (6, 7), and it has been proposed that infection may result in a benign clonal expansion of HTLV-I-infected CD4+ T cells (8). This view has been supported by studies of Wattel and colleagues (9, 10, 11) who, using ligation-mediated inverse PCR amplification of the provirus with cellular flanking sequences, concluded that clonal expansion of the infected cells is common in all HTLV-I-infected individuals. Studies to evaluate clonal expansion of responding T cells in infected individuals have been somewhat limited. Cloning studies (12) and more recently an investigation using a PCR-based single-strand conformation polymorphism (SSCP) assay (13) have suggested the presence of oligoclonal accumulation of responding T cells in peripheral blood, with the latter study also showing human leukocyte Ag (HLA) class I-restricted CTL clones in patients with HAM/TSP. However, these studies were somewhat limited in that they were conducted on unfractionated peripheral blood lymphocytes, and no attempts were made to demonstrate oligoclonality within isolated T cell populations. In the present study we have employed a recently established multiplex PCR assay to analyze the complementarity-determining region 3 (CDR3) length variation in TCR Vβ transcripts to evaluate the clonal expansion within fractionated T cell subsets from HTLV-I-infected individuals with and without disease. In addition, we have determined the predicted amino acid sequences of the CDR3 regions by direct nucleotide sequencing methods to determine whether there is a bias in the motifs present in the expanded populations in different clinical conditions.

Four HTLV-I ACs, five patients with HAM, and one patient with ATL were examined. Uninfected controls were 60 normal individuals who were analyzed in a previous study using the identical multiplex PCR assay under identical conditions (17). Three clinically asymptomatic individuals with HTLV-II served as additional control subjects. These were two males, age 46 and 58, and one female, age 53.

HLA Ags were determined serologically by the standard National Institutes of Health microcytotoxicity test using sera that were standardized to the criteria and nomenclature of the 11th International Histocompatibility Workshop (14). Further HLA DNA typing of HLA class II DRB1* and DQB1* alleles were conducted by the PCR/RFLP method (15, 16). The results are shown in Table I.

Table I.

Demographic features and HLA typing of HTLV-1-infected individualsa

HLA Class I IndividualAgeSexHLA Class IIDRB1DRB1DQB1DQB1
AABBCC
AC1 47 11 61  1401 0803 0601 05031 
AC2 36 24 54 61 0405 0405 0401 0401 
AC3 52 11 35 55 1501 1401 05031 0602 
AC4 52 24 26 39 51 1501 1403 0602 0301 
HAM1 55 26 35 61  0901 1101 03032 0302 
HAM2 39 11 24 13 54 0901 1201 03032 0301 
HAM3 51 24 51 61  0901 1201 03032 0301 
HAM4 60 11 31 51 61  0405 0408 0401 0301 
HAM5 44 11 26 54 60 0405 0803 0405 0601 
ATL1 56     0901 1403 03032 0301 
HLA Class I IndividualAgeSexHLA Class IIDRB1DRB1DQB1DQB1
AABBCC
AC1 47 11 61  1401 0803 0601 05031 
AC2 36 24 54 61 0405 0405 0401 0401 
AC3 52 11 35 55 1501 1401 05031 0602 
AC4 52 24 26 39 51 1501 1403 0602 0301 
HAM1 55 26 35 61  0901 1101 03032 0302 
HAM2 39 11 24 13 54 0901 1201 03032 0301 
HAM3 51 24 51 61  0901 1201 03032 0301 
HAM4 60 11 31 51 61  0405 0408 0401 0301 
HAM5 44 11 26 54 60 0405 0803 0405 0601 
ATL1 56     0901 1403 03032 0301 
a

The study included four asymptomatic carriers (AC1–AC4), five patients with HAM/TSP (HAM1–HAM5), and one patient with adult T cell leukemia (ATL1).

PBMCs were obtained by centrifugation over Ficoll-Hypaque. Cells were washed twice in RPMI 1640 with 1% FCS and resuspended in PBS with 1% FCS at a concentration of 10 × 106 cells/ml. Positive selection for CD8+ T cells was conducted by incubating the PBMC with anti-CD8 immunomagnetic beads (Dynal, Great Neck, NY) for 30 min at 4°C on a rotating shaker, as recommended by the manufacturer. The unbound cells were then incubated with anti-CD4 immunomagnetic beads for selection of CD4+ T cells. The cells bound to the beads were placed directly into RNAzolB (Biotex, Houston, TX) for isolation of total RNA.

Total RNA (2 μg) from the selected T cell populations was used for the first-strand cDNA synthesis using a TCR B-chain C region primer, 3CB3 (see Table II). The cDNA synthesis was performed with Moloney murine leukemia virus reverse transcriptase in buffer supplied by manufacturer (Life Technologies, Gaithersburg, MD) at 42°C for 1 h in a total volume of 120 μl. Specific primers used in RT-PCR for CDR3 of TCR BV-chains are shown in Table II. Specific combinations of two or three Vβ (BV)-specific forward primers (20 pmol each) were used for each multiplex PCR. Each reaction also contained 20 pmol of a reverse primer specific for the C region (3CB1), out of which 3 pmol were end labeled with 32P using T4 kinase (Life Technologies). The BV primer combinations were selected on the basis of the location of each BV specific primer with respect to the end of the BV region. The 12 different reaction sets were as follows; A, TCRBV1, 18, 23; B, BV2 4, 8; C, BV3, 13S1; D, BV5S2, 5S1; E, BV6, 20; F, BV7, 22; G, BV9, 16; H, BV11, 12; I, BV15, 13S2; J, BV14, 17; K, BV19, 24; and L, BV10, 21. A representative multiplex PCR assay is shown in Fig. 1. A total of 10 μl of the cDNA was used for each PCR. Conditions for the PCR were as follow: After initial denaturation at 94°C for 5 min, 35 cycles were conducted in a DNA thermocycler (model 9600; Perkin-Elmer, Norwalk, CT) Each cycle consisted of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 1 min. PCR buffer conditions were 10 mM Tris-HCl (pH 8.3), 2 mM MgCl2, and 50 mM KCL, with 20 pmol of each primer in a 100-μl reaction volume. After 35 cycles, an additional extension at 72°C for 10 min was conducted. Five microliters of the amplified products were loaded on a standard 6% polyacrylamide sequencing gel. Bands (spaced 3 bp apart) were visualized after overnight exposure to Kodak AR film (Rochester, NY). The radioactive bands were also analyzed and quantitated using a PhosphorImager (PhosphorImager SF; Molecular Dynamics, Sunnyvale, CA).

Table II.

Primers used in the analysis of CDR3 length

PrimerSequence
First-strand cDNA synthesis primer  
3CB3 5′-ACTGTGCACCTCCTTCCCATT-3′ 
Variable region sense primers  
BV1 5′-CAACAGTTCCCTGACTTGCAC-3′ 
BV2 5′-TCAACCATGCAAGCCTGACCT-3′ 
BV3 5′-TCTAGAGAGAAGAAGGAGCGC-3′ 
BV4 5′-CATATGAGAGTGGATTTGTCATT-3′ 
BV5S1 5′-TTCAGTGAGACACAGAGAAAC-3′ 
BV5S2 5′-CCTAACTATAGCTCTGAGCTG-3′ 
BV6 5′-AGGCCTGAGGGATCCGTCTC-3′ 
BV7 5′-CTGAATGCCCCAACAGCTCTC-3′ 
BV8 5′-TACTTTAACAACAACGTTCCG-3′ 
BV9 5′-AAATCTCCAGACAAAGCTCAC-3′ 
BV10 5′-CAAAAACTCATCCTGTACCTT-3′ 
BV11 5′-ACAGTCTCCAGAATAAGGACG-3′ 
BV12 5′-GACAAAGGAGAAGTCTCAGAT-3′ 
BV13S1 5′-GACCAAGGAGAAGTCCCCAAT-3′ 
BV13S2 5′-GTTGGTGAGGGTACAACTGCC-3′ 
BV14 5′-TCTCGAAAAGAGAAGAGGAAT-3′ 
BV15 5′-GTCTCTCGACAGGCACAGGCT-3′ 
BV16 5′-GAGTCTAAACAGGATGAGTCC-3′ 
BV17 5′-CACAGATAGTAAATGACTTTCAG-3′ 
BV18 5′-GAGTCAGGAATGCCAAAGGAA-3′ 
BV19 5′-CCCCAAGAACGCACCCTGC-3′ 
BV20 5′-TCTGAGGTGCCCCAGAATCTC-3′ 
BV21 5′-GATATGAGAATGAGGAAGCAG-3′ 
BV22 5′-CAGAGAAGTCTGAAATATTCGA-3′ 
BV23 5′-TCATTTCGTTTTATGAAAAGATGC-3′ 
BV24 5′-AAAGATTTTAACAATGAAGCAGAC-3′ 
Constant region antisense primer  
3CB1 5′-TGCTTCTGATGGCTCAAACAC-3′ 
Primers used for CDR3 sequence analysis  
BJ1S1 5′-AACTGTGAGTCTGGTGCCTT-3′ 
BJ1S2 5′-ACGGTTAACCTGGTCCCCGA-3′ 
BJ1S3 5′-CTCTACAACAGTGAGCCAAC-3′ 
BJ1S4 5′-GACAGAGAGCTGGGTTCCAC-3′ 
BJ1S5 5′-TGGAGAGTCGAGTCCCATCA-3′ 
BJ1S6 5′-TGAGCCTGGTCCCATTCCCA-3′ 
BJ2S1 5′-CCTCTAGCACGGTGAGCCGT-3′ 
BJ2S2 5′-TACGGTCAGCCTAGAGCCTT-3′ 
BJ2S3 5′-CTGTCAGCCGGGTGCCTGGG-3′ 
BJ2S4 5′-CTGAGAGCCGGGTCCCGGCG-3′ 
BJ2S5 5′-CCTCGAGCACCAGGAGCCGC-3′ 
BJ2S6 5′-CCTGCTGCCGGCCCCGAAAG-3′ 
BJ2S7 5′-TGACCGTGAGCCTGGTGCCC-3′ 
PrimerSequence
First-strand cDNA synthesis primer  
3CB3 5′-ACTGTGCACCTCCTTCCCATT-3′ 
Variable region sense primers  
BV1 5′-CAACAGTTCCCTGACTTGCAC-3′ 
BV2 5′-TCAACCATGCAAGCCTGACCT-3′ 
BV3 5′-TCTAGAGAGAAGAAGGAGCGC-3′ 
BV4 5′-CATATGAGAGTGGATTTGTCATT-3′ 
BV5S1 5′-TTCAGTGAGACACAGAGAAAC-3′ 
BV5S2 5′-CCTAACTATAGCTCTGAGCTG-3′ 
BV6 5′-AGGCCTGAGGGATCCGTCTC-3′ 
BV7 5′-CTGAATGCCCCAACAGCTCTC-3′ 
BV8 5′-TACTTTAACAACAACGTTCCG-3′ 
BV9 5′-AAATCTCCAGACAAAGCTCAC-3′ 
BV10 5′-CAAAAACTCATCCTGTACCTT-3′ 
BV11 5′-ACAGTCTCCAGAATAAGGACG-3′ 
BV12 5′-GACAAAGGAGAAGTCTCAGAT-3′ 
BV13S1 5′-GACCAAGGAGAAGTCCCCAAT-3′ 
BV13S2 5′-GTTGGTGAGGGTACAACTGCC-3′ 
BV14 5′-TCTCGAAAAGAGAAGAGGAAT-3′ 
BV15 5′-GTCTCTCGACAGGCACAGGCT-3′ 
BV16 5′-GAGTCTAAACAGGATGAGTCC-3′ 
BV17 5′-CACAGATAGTAAATGACTTTCAG-3′ 
BV18 5′-GAGTCAGGAATGCCAAAGGAA-3′ 
BV19 5′-CCCCAAGAACGCACCCTGC-3′ 
BV20 5′-TCTGAGGTGCCCCAGAATCTC-3′ 
BV21 5′-GATATGAGAATGAGGAAGCAG-3′ 
BV22 5′-CAGAGAAGTCTGAAATATTCGA-3′ 
BV23 5′-TCATTTCGTTTTATGAAAAGATGC-3′ 
BV24 5′-AAAGATTTTAACAATGAAGCAGAC-3′ 
Constant region antisense primer  
3CB1 5′-TGCTTCTGATGGCTCAAACAC-3′ 
Primers used for CDR3 sequence analysis  
BJ1S1 5′-AACTGTGAGTCTGGTGCCTT-3′ 
BJ1S2 5′-ACGGTTAACCTGGTCCCCGA-3′ 
BJ1S3 5′-CTCTACAACAGTGAGCCAAC-3′ 
BJ1S4 5′-GACAGAGAGCTGGGTTCCAC-3′ 
BJ1S5 5′-TGGAGAGTCGAGTCCCATCA-3′ 
BJ1S6 5′-TGAGCCTGGTCCCATTCCCA-3′ 
BJ2S1 5′-CCTCTAGCACGGTGAGCCGT-3′ 
BJ2S2 5′-TACGGTCAGCCTAGAGCCTT-3′ 
BJ2S3 5′-CTGTCAGCCGGGTGCCTGGG-3′ 
BJ2S4 5′-CTGAGAGCCGGGTCCCGGCG-3′ 
BJ2S5 5′-CCTCGAGCACCAGGAGCCGC-3′ 
BJ2S6 5′-CCTGCTGCCGGCCCCGAAAG-3′ 
BJ2S7 5′-TGACCGTGAGCCTGGTGCCC-3′ 
FIGURE 1.

Schematic representation of the relative locations of three different TCR BV upstream primers with the common radiolabeled CB reverse primer employed in the multiplex RT-PCR to assay CDR3 length.

FIGURE 1.

Schematic representation of the relative locations of three different TCR BV upstream primers with the common radiolabeled CB reverse primer employed in the multiplex RT-PCR to assay CDR3 length.

Close modal

cDNAs were reamplified using a single TCR BV segment primer and an unlabeled 3CB1 primer. The amplified product was used as a substrate for DNA sequencing using the 3CB1 or BJ-R (reverse primer specific for the BJ region) primer, following purification over PCR Prep DNA purification columns (Promega, Madison, WI). Direct sequencing of the PCR products was conducted with fluorescent dideoxy terminators and analyzed on a model 373A Automated Sequenator (Applied Biosystems, Foster City, CA). Nucleotide sequences were further confirmed using specific BJ reverse primers (Table II).

Restriction in CDR3 length within a particular BV segment is visualized as a “dominant band” and based on its intensity with respect to the rest of the bands within the TCR BV-specific PCR product. The radioactive gels were scanned using a PhosphorImager, and specific criteria were used to define a band as “dominant” were that >50% of the counts within a V segment/family were contained this band. The clonality of the band was established by direct sequencing of the PCR products with the 3CB1 primer. Pilot studies demonstrated that when the counts within the dominant band were 50% or greater of the entire BV family, a single readable sequence was obtained using the 3CB1 primer. Sequencing with a specific BJ-R primer (selected on the basis of the first 3CB1 primed sequence) yielded a clearly readable sequence in an additional 35% of cases. Thus, in all, 82% of the cases in which the 50% criteria for dominance were met, direct sequencing of the PCR product yielded a single dominant sequence (17).

The multiplex PCR assay was used to assess the clonality of 26 TCR-BV families in the separated CD4+ and CD8+ T lymphocytes of five patients with HAM/TSP, four HTLV-I ACs, and one patient with ATL. Fig. 2 shows a typical autoradiogram of the PCR products analyzed by electrophoresis on a 6% polyacrylamide gel from a patient with HAM/TSP. In this individual, dominant bands of a single CDR3 length were observed in both the CD4+ and CD8+ T lymphocyte populations in a large number of different BV families. Table III summarizes the TCR BV families shown to be clonally expanded in both the CD4+ and CD8+ T lymphocyte populations in all 10 individuals studied. The results demonstrated that clonal expansion of both CD4+ and CD8+ T lymphocytes occurs in both asymptomatic carriers and patients with HAM/TSP. Moreover, while the total number of expanded clones in the CD8+ T lymphocyte population was much greater (3–10 clones) than that of the CD4+ T lymphocytes (1–3 clones), no appreciable differences were observed between asymptomatic carriers and patients with HAM/TSP. Similarly we were unable to observe differences in specific V-β expansion in patients with HAM/TSP compared with asymptomatic carriers. Even after stratification of HLA phenotype there was no evidence of expansion involving a unique T cell repertoire. Within the CD4 T cell populations, we observed clonal expansion in four of five patients with HAM/TSP involving a total of 18 different clones. In the asymptomatic carriers, clonal expansion was observed in two of four individuals and this involved 7 different clones (Table III). In one patient with ATL, we observed one specific band in the CD4 population, Vβ 7. In contrast, clonal expansion was not observed in any of the CD4+ T cell populations in three control HTLV-II-infected individuals. In addition we have shown in previous studies using the same PCR assay that clonal expansion within CD4+ T cell population of uninfected individuals occurs rarely, if at all (17). In the CD8 population, the T cell populations which did not exhibit clonal expansion were seven Vβs (3, 7, 10, 15, 17, 22, 23) in HAM/TSP and three Vβs (6, 7, 18) in HTLV-I carriers. Table III shows that overall Vβ utilization was extremely diverse, and no restricted or consistent pattern was obvious in either the asymptomatic carriers or HAM/TSP patients.

FIGURE 2.

Results of a representative multiplex RT-PCR assay for CDR3 length in a patient with HAM/TSP (patient 5). Peripheral blood CD4+ and CD8+T lymphocytes were analyzed separately after immunomagnetic bead selection. Lanes are labeled 4 and 8, respectively, and 12 sets of primers were used in the PCR as outlined in Table II. PCR products were analyzed by electrophoresis on 6% polyacrylamide gels as described in Materials and Methods.

FIGURE 2.

Results of a representative multiplex RT-PCR assay for CDR3 length in a patient with HAM/TSP (patient 5). Peripheral blood CD4+ and CD8+T lymphocytes were analyzed separately after immunomagnetic bead selection. Lanes are labeled 4 and 8, respectively, and 12 sets of primers were used in the PCR as outlined in Table II. PCR products were analyzed by electrophoresis on 6% polyacrylamide gels as described in Materials and Methods.

Close modal
Table III.

TCRBV utilization in HTLV infections

IndividualT Cell SubpopulationTCR BV Oligoclonality
HTLV-I AC   
CD4 None 
 CD8 1, 4, 8, 12, 13S1, 14, 20, 22 
CD4 None 
 CD8 15, 20, 24 
CD4 4, 7, 8, 11, 12 
 CD8 1, 2, 4, 9, 10, 13S2, 15, 19, 22, 23 
CD4 5S1, 17 
 CD8 1, 3, 4, 6, 9, 12, 13S2, 14, 15, 21 
HAM   
CD4 13S2 
 CD8 4, 5S1, 9, 13S1, 19, 21, 24 
CD4 
 CD8 2, 11, 12, 13S2, 14, 18, 20, 24 
CD4 None 
 CD8 5S1, 11, 13S2 
CD4 24 
 CD8 2, 4, 8 
CD4 4, 18, 22 
 CD8 1, 4, 6, 8, 13S1, 16, 19, 20 
ATL   
   
CD4 
 CD8 5S2, 9, 10, 11, 17, 20, 22, 24 
HTLV-11 AC   
CD4 None 
 CD8 5S1, 8, 16, 21 
CD4 None 
 CD8 6, 9, 12, 16, 17 
CD4 None 
 CD8 10, 14, 22 
IndividualT Cell SubpopulationTCR BV Oligoclonality
HTLV-I AC   
CD4 None 
 CD8 1, 4, 8, 12, 13S1, 14, 20, 22 
CD4 None 
 CD8 15, 20, 24 
CD4 4, 7, 8, 11, 12 
 CD8 1, 2, 4, 9, 10, 13S2, 15, 19, 22, 23 
CD4 5S1, 17 
 CD8 1, 3, 4, 6, 9, 12, 13S2, 14, 15, 21 
HAM   
CD4 13S2 
 CD8 4, 5S1, 9, 13S1, 19, 21, 24 
CD4 
 CD8 2, 11, 12, 13S2, 14, 18, 20, 24 
CD4 None 
 CD8 5S1, 11, 13S2 
CD4 24 
 CD8 2, 4, 8 
CD4 4, 18, 22 
 CD8 1, 4, 6, 8, 13S1, 16, 19, 20 
ATL   
   
CD4 
 CD8 5S2, 9, 10, 11, 17, 20, 22, 24 
HTLV-11 AC   
CD4 None 
 CD8 5S1, 8, 16, 21 
CD4 None 
 CD8 6, 9, 12, 16, 17 
CD4 None 
 CD8 10, 14, 22 

To determine whether the CDR3 of the TCR in patients with HAM/TSP may be restricted or conserved, we conducted extensive nucleotide sequencing of this region. Tables IV–VI showed a representative analysis of the predicted amino acid sequences of the CDR3 regions in asymptomatic HTLV-I carriers, patients with HAM/TSP, and in the one patient with ATL. The average length of the CDR3 region was not different among patients with HAM/TSP (10.66 in CD4, 10.48 in CD8), ATL (10 in CD4, 10.25 in CD8), and HTLV-I ACs (10.29 in CD4, 10.48 in CD8). PG or related sequence (PXG) motifs were more frequently observed in CD8 T cell populations of patients with HAM/TSP than in those of HTLV-I carriers. Eight of 29 clones (27.6%) had this sequence in HAM/TSP compared with 2 of 31 clones (6.5%) in HTLV-I carriers. However these differences were not of statistical significance when analyzed by Fisher’s exact test (χ2 = 3.417, p = 0.06). It was interesting to note that 4 of 8 clones having a PG or related motif were from HAM/TSP patients bearing HLA-A2. LXG motifs were more frequently observed in HTLV-I carriers (6 of 38; 15.8%) than in HAM/TSP (3 of 35; 8.6%). JB utilization showed some conservation in that JB2.1 was detected in 50% of patients with HAM/TSP and in 29% of asymptomatic carriers.

In contrast to CD4+ T cells, it has been shown that CD8+ T cells and particularly CD45RO+, CD57+, and CD28 populations may exhibit oligoclonality in normal individuals (17, 18, 19, 20). In a previous study that employed the same PCR-based assay used in our present study, we demonstrated that 72% of normal subjects had evidence of oligoclonality in the CD8+ T cell subset, with the mean number of clones per subject being reported to be 3.8 (17). Frequent oligoclonal expansion has also been observed in bone marrow transplant recipients and in patients with rheumatoid arthritis and multiple sclerosis (21, 22). With respect to HTLV-I infection, there have only been limited studies on the clonal expansion of peripheral blood lymphocytes. HTLV-I preferentially infects CD4+ T lymphocytes (6, 7), and it has been suggested that in many cases this may lead to a benign clonal expansion of the infected population(s) (8, 9, 10, 11). In addition, several studies have shown that in both ACs and in patients with HAM/TSP there is a vigorous CD8+ T lymphocyte CTL response (23, 24, 25, 26, 27, 28). One study on TCR variable regions conducted on Tax-specific CTL clones established from peripheral blood of HAM/TSP patients suggested a limited Vα and Vβ utilization (28), and sequence analysis of the CDR3 regions showed evidence of an oligoclonal expansion in responding T cells (12). A more detailed study on TCR Vβ regions based on analysis of cDNA from central nervous system lesions of HAM/TSP patients suggested that T cells containing restricted Vβ CDR3 motifs become activated upon HTLV-I infection (29). Recently, Höger et al. (13) clearly demonstrated the accumulation of T cell clones in patients with HAM/TSP using PCR-based SSCP methods which allowed the detection of conformational polymorphism of the CDR3 regions of TCR Vβ. This method detected T cell oligoclonality as labeled bands in a background smear pattern following SSCP gel electrophoresis. The numbers of reported clones ranged from 65 to 94 and were much higher in patients with HAM/TSP compared with ACs. However, these studies were limited in that no attempts were made to differentiate expansion in isolated CD4+ and CD8+ cell populations.

The CDR3 loops of both α- and β-chains are thought to carry the fine specificity of Ag recognition by T cells (30). Because nucleotide transferases add or remove nucleotides at the various V-D and D-J junctions during recombination, the CDR3 region of any V-J combination may vary in length by as many as 6–8 amino acids (31). A recently developed multiplex PCR approach that allows for the quantitative evaluation of the CDR3 length profile of each Vβ segment families was utilized in our study (17, 18, 19, 20, 21, 22). The detection of biased peaks compared with the expected symmetrical background distribution of the several bands can be regarded as evidence of clonality within the T cell repertoire, and Ag-driven clonal T cell expansion can be evaluated more conveniently as compared with the SSCP method described above. The major difference between the SSCP method and our procedure is related to the detection of clonality based on conformation vs the length of the CDR3 regions. In our studies, we could demonstrate the following. 1) Mono- or polyclonal expansion of CD4+ T cells was confirmed in two of four ACs and in four of five patients with HAM/TSP. In the one patient with ATL, a specific clone bearing Vβ 7 was detected in the CD4+ T cell subset. 2) Accumulated oligoclonality within the CD8+ T cell subset was evident in all subjects, including ACs (3–10 clones), HAM/TSP patients (3–8 clones), and an ATL patient (8 clones). The mean value of the number of clones was 6.8 clones per individual. No statistically significant differences in the average number of clones were observed between individuals with HAM/TSP and ACs. 3) The repertoire of the clonally expanded T cells was extremely diverse and there was no bias in Vβ gene usage. 4) There was no statistically significant restriction in the CDR3 motifs of the TCR Vβs. 5) In two patients with HAM/TSP, who were HLA-A2 positive, PG, or related motifs (PXG) in the Vβ CDR3 sequence were detected in four predominant clones.

The clonal expansion within CD4+ T cells observed in our study would seem to be related at least in part to the proliferation of cells as a result of virus infection. HTLV-I has a preferential and often exclusive tropism for CD4+ T lymphocytes and clonal expansion of HTLV-I-infected cells has been predicted by Southern blot hybridization assays (8, 32), and more recently by ligation mediated inverse PCR amplification methods (9, 10, 11). Our study provides the first direct demonstration of in vivo clonal expansion of infected cells within the fractionated CD4+ T cell subset. However, further studies that would require the isolation of individually expanded populations with subsequent molecular analysis to detect the presence of integrated HTLV-I provirus are required to definitely confirm the association of infection with expansion. In our experience, such studies are technically difficult in that the successful isolation of the expanded CD4+ T lymphocyte population requires very large quantities of peripheral blood mononuclear cells as starting material, and this is difficult to obtain from most patients. Moreover, these studies are also restricted by the limited availability of specific Vβ Abs that would be required to isolate the expanded population. However, at present we are attempting to overcome these difficulties and carry out such studies. The view that clonal expansion of CD4+ T lymphocyte populations is due to HTLV-I infection is also supported by the observations that expansion is only rarely observed in uninfected normal individuals and was not observed in any of three HTLV-II-infected individuals included in this study. In contrast to HTLV-I, HTLV-II has a preferential tropism for CD8+ T lymphocytes (34), and this would be consistent with the absence of clonal expansion of CD4+T lymphocytes in HTLV-II infection and its presence in HTLV-I infection.

The present studies also provide the first description of the frequent clonal T cell expansions within fractionated CD8+ cell population (6.8 clones per individual), which suggests there is Ag-driven polyclonal CD8+ cell expansion in HTLV-I-infected individuals. However, further studies will also be required to confirm this and to identify the Ags involved. While clonal expansion of CD8+ cell populations certainly occurs in normal uninfected individuals (17, 18, 19, 20), the number of expanded clones in the HTLV-I-infected group is higher than would be expected. The reason for the discordance in the numbers of clones (per subject) with the previously reported results using the PCR-based SSCP assay (13) (65–94 clones reported for HAM/TSP patients) is unknown but may partially result from the differences in the methods employed. Our results also differ from this study in that we could not demonstrate differences in the number of expanded clones between ACs and patients with HAM/TSP. However, direct comparison of the two studies is very difficult, as the latter study also did not differentiate between expansion of the CD4 and CD8 populations. Hara et al. (29) suggested the presence of restriction in CDR3 motifs of infiltrating lymphocytes in the spinal cord lesions of HAM/TSP patients as encephalitis-related motifs (LXG). We found no evidence for this. LXG motifs were only detected in 3 of 35 predominant clones identified in patients with HAM/TSP, but were also detected in ACs. PG or related motifs (PXG) of the TCR Vβ CDR3 regions, which previously were reported as structural motifs of the HTLV-I Tax-specific CTL clones restricted by HLA-A2, were detected in eight predominant clones in patients with HAM/TSP (four of these clones were also identified in HLA-A2-bearing patients). However, based on the innate tendency of the terminal deoxytransferase to increase the incorporation of glycine residues (33), the evaluation of CDR3 motifs involving G residues requires careful interpretation.

In HAM/TSP patients, both the high proviral DNA load (35, 36, 37, 38) and the extremely low levels of viral replication in PBLs (38) are accompanied by higher and active humoral immune responses (40– 42) and a higher frequency of HTLV-I-specific CD8+ CTLs compared with ACs (25). HLA haplotype analysis has been rewarding in pinpointing the role of cellular immune responses against HTLV-I in the pathogenesis of HAM/TSP (41) and a proliferative potency of the PBLs responding to HTLV-I in HAM/TSP patients has received attention as an in vitro equivalent of the cellular inflammation in the central nervous system of the patients (43, 44, 45, 46). Taken together, the data support the involvement and importance of anti-HTLV-I CTL activities in the pathogenesis of HAM/TSP (23, 24, 25). HTLV-I-specific CD8+ CTLs have been demonstrated directly in lymphocytes in the peripheral blood and CSF of HAM/TSP patients (23, 24, 25, 47) and in the peripheral blood of ACs (26, 27). Although the impairment of some nonspecific cellular immune activities has been reported in patients with HAM/TSP (48, 49, 50), a beneficial effect of immunosuppressive therapies in a majority of the patients is well established (51). The detection of oligoclonal expansions of CD8+ T cells in HTLV-I-infected individuals as demonstrated in the present study may preferentially reflect the presence of the HTLV-I-specific CTL clones in these subjects. In our comparative analysis, there was no significant difference in the TCR Vβ CDR3 length profile between HAM/TSP patients and ACs, suggesting that the presence of oligoclonal expansion of CD8+ T cells may be only one of the prerequisites for the development of disease.

Table IV.

Predicted amino acid sequence of the CDR3 region of TCR BV-chains in HTLV-I-infected ACs (AC1–4)

IndividualSubpopulationBVBV EndN-D-NBJBCCDR3 Length
AC1 CD8 BV1 YFCASS VGLAGGP DTQY..BJ2S3 BC2 12 
 CD8 BV4 YLCSV GRTDP YEQY..BJ2S7 BC2 
 CD8 BV8 YFCAS RTSEI NTGELF..BJ2S2 BC2 11 
 CD8 BV12 YFCASS GDGR GYT..BJ1S2 BC1 
 CD8 BV13S1 YFCASS SGPTGWA EAF..BJ1S1 BC1 11 
 CD8 BV14 YFCASS LSRGLL NEQF..BJ2S1 BC2 11 
 CD8 BV20 YLCAW RGSGSP YNEQF..BJ2S1 BC2 11 
 CD8 BV22 YFCASS GTGSG ETQY..BJ2S5 BC2 10 
AC2 CD8 BV15 YFCATS EGTSGIYS NEQF..BJ2S1 BC2 13 
 CD8 BV20 YLCAWS VASTQET QY..BJ2S5 BC2 10 
 CD8 BV24 YLCAT NVDE TDTQY..BJ2S3 BC2 
AC3 CD4 BV4 YLCS ATGT GANVLT..BJ2S6 BC2 
 CD4 BV7 YLCASS GLGGG NEQF..BJ2S1 BC2 10 
 CD4 BV8 YFCASS VDGD TGELF..BJ2S2 BC2 10 
 CD4 BV11 YLCASS DTGGPS SYEQY..BJ2S7 BC2 12 
 CD4 BV12 YFCA TIDAI STDTQY..BJ2S3 BC2 10 
 CD8 BV1 YFCASS GTQGH EQF..BJ2S1 BC2 
 CD8 BV2 YICSAR ATMGF QETQY..BJ2S5 BC2 11 
 CD8 BV4 YLCSV DGIGD TEAF..BJS1 BC1 
 CD8 BV9 YFCASS QDASGFSH EQF..BJ2S1 BC2 11 
 CD8 BV10 YFCAS RIRAGGA YNEQF..BJ2S1 BC2 12 
 CD8 BV13S2 YFCAS RGWDYG SPLH..BJ1S6 BC1 10 
 CD8 BV15 YFCAT RGRGLAGLLA DTQY..BJ2S3 BC2 14 
 CD8 BV19 YLCASS QRRDRVK ETQY..BJ2S5 BC2 12 
 CD8 BV22 YFCAS NLAGVL DEQY..BJ2S7 BC2 10 
 CD8 BV23 YFCASS PAGSR TGELF..BJ2S2 BC2 11 
AC4 CD4 BV5S1 YLCASS LQGKK TEAF..BJ1S1 BC1 10 
 CD4 BV17 YLCASS PGLAGVG EQF..BJ2S1 BC2 11  
 CD8 BV1 YFCASS VRG SPLH..BJ1S6 BC1 
 CD8 BV3 YLCAS RLDRAI SYEQY..BJ2S7 BC2 11 
 CD8 BV4 YLCSVE EGRVG F..BJ2S1 BC2 
 CD8 BV6 YLCASS LWQG YGYT..BJ1S2 BC1 
 CD8 BV9 YFCASS LGTVG EKLF..BJ1S4 BC1 10 
 CD8 BV12 YFCA IRRLVA YNEQF..BJ2S1 BC1 10 
 CD8 BV13S2 YFCASS PLWLAGS SYQY..BJ2S7 BC2 13 
 CD8 BV14 YFCASS FLTSGI TDTQY..BJ2S3 BC2 12 
 CD8 BV15 YFCATS GRQVE QPQH..BJ1S5 BC1 10 
 CD8 BV21 YLCASS FRDG SYNEQF..BJ2S1 BC2 11 
IndividualSubpopulationBVBV EndN-D-NBJBCCDR3 Length
AC1 CD8 BV1 YFCASS VGLAGGP DTQY..BJ2S3 BC2 12 
 CD8 BV4 YLCSV GRTDP YEQY..BJ2S7 BC2 
 CD8 BV8 YFCAS RTSEI NTGELF..BJ2S2 BC2 11 
 CD8 BV12 YFCASS GDGR GYT..BJ1S2 BC1 
 CD8 BV13S1 YFCASS SGPTGWA EAF..BJ1S1 BC1 11 
 CD8 BV14 YFCASS LSRGLL NEQF..BJ2S1 BC2 11 
 CD8 BV20 YLCAW RGSGSP YNEQF..BJ2S1 BC2 11 
 CD8 BV22 YFCASS GTGSG ETQY..BJ2S5 BC2 10 
AC2 CD8 BV15 YFCATS EGTSGIYS NEQF..BJ2S1 BC2 13 
 CD8 BV20 YLCAWS VASTQET QY..BJ2S5 BC2 10 
 CD8 BV24 YLCAT NVDE TDTQY..BJ2S3 BC2 
AC3 CD4 BV4 YLCS ATGT GANVLT..BJ2S6 BC2 
 CD4 BV7 YLCASS GLGGG NEQF..BJ2S1 BC2 10 
 CD4 BV8 YFCASS VDGD TGELF..BJ2S2 BC2 10 
 CD4 BV11 YLCASS DTGGPS SYEQY..BJ2S7 BC2 12 
 CD4 BV12 YFCA TIDAI STDTQY..BJ2S3 BC2 10 
 CD8 BV1 YFCASS GTQGH EQF..BJ2S1 BC2 
 CD8 BV2 YICSAR ATMGF QETQY..BJ2S5 BC2 11 
 CD8 BV4 YLCSV DGIGD TEAF..BJS1 BC1 
 CD8 BV9 YFCASS QDASGFSH EQF..BJ2S1 BC2 11 
 CD8 BV10 YFCAS RIRAGGA YNEQF..BJ2S1 BC2 12 
 CD8 BV13S2 YFCAS RGWDYG SPLH..BJ1S6 BC1 10 
 CD8 BV15 YFCAT RGRGLAGLLA DTQY..BJ2S3 BC2 14 
 CD8 BV19 YLCASS QRRDRVK ETQY..BJ2S5 BC2 12 
 CD8 BV22 YFCAS NLAGVL DEQY..BJ2S7 BC2 10 
 CD8 BV23 YFCASS PAGSR TGELF..BJ2S2 BC2 11 
AC4 CD4 BV5S1 YLCASS LQGKK TEAF..BJ1S1 BC1 10 
 CD4 BV17 YLCASS PGLAGVG EQF..BJ2S1 BC2 11  
 CD8 BV1 YFCASS VRG SPLH..BJ1S6 BC1 
 CD8 BV3 YLCAS RLDRAI SYEQY..BJ2S7 BC2 11 
 CD8 BV4 YLCSVE EGRVG F..BJ2S1 BC2 
 CD8 BV6 YLCASS LWQG YGYT..BJ1S2 BC1 
 CD8 BV9 YFCASS LGTVG EKLF..BJ1S4 BC1 10 
 CD8 BV12 YFCA IRRLVA YNEQF..BJ2S1 BC1 10 
 CD8 BV13S2 YFCASS PLWLAGS SYQY..BJ2S7 BC2 13 
 CD8 BV14 YFCASS FLTSGI TDTQY..BJ2S3 BC2 12 
 CD8 BV15 YFCATS GRQVE QPQH..BJ1S5 BC1 10 
 CD8 BV21 YLCASS FRDG SYNEQF..BJ2S1 BC2 11 
Table V.

Predicted amino acid sequence of the CDR3 region of TCR BV-chains in patients with HAM/TSP (HAM1-5)

IndividualSubpopulationBVBV EndN-D-NBJBCCDR3 length
HAM1 CD4 BV13S2 YFCASS SRPG GANVLT..BJ2S6 BC2 11 
 CD8 BV4 YLCSV TGASSGD EQF..BJ2S1 BC1 10 
 CD8 BV9 YFCASS SGPLEGS YEQY..BJ2S7 BC2 12 
 CD8 BV5S1 YLCASS LVPG SYNEQF..BJ2S1 BC2 11 
 CD8 BV13S1 YFCASS CPGQGV ETQY..BJ2S5 BC2 11 
 CD8 BV19 YLCASS RPTGTGAN EQY..BJ2S7 BC2 12 
 CD8 BV21 YLCASS PELGQF NEQF..BJ2S1 BC2 11 
 CD8 BV24 YLCAT RDRGRG NEQF..BJ2S1 BC2 10 
HAM2 CD4 BV8 YFCASS SPHRGV NEQF.BJ2S1 BC1 11 
 CD8 BV2 YICS TRGWGRRS YEQY..BJ2S7 BC2 11 
 CD8 BV11 YLCAS ARQL YNEQF..BJ2S1 BC2 
 CD8 BV12 YFCA ISYSGEG YEQY..BJ2S7 BC2 10 
 CD8 BV13S2 YFCAS RRGGRG EQF..BJ2S1 BC2 
 CD8 BV14 YFCASS LVG STDTQY..BJ2S3 BC1 10 
 CD8 BV18 YFCASS PDREI DTQY..BJ2S3 BC2 10 
 CD8 BV20 YLCAWS GPSCLG EKLF..BJ1S4 BC1 11 
 CD8 BV24 YLCATS RIAG ETQY..BJ2S5 BC2 
HAM3 CD8 BV5S1 YLCAS RMDRGY YNEQF..BJ2S1 BC2 11 
 CD8 BV11 YLCASS QRGGE ETQY..BJ2S5 BC2 10 
 CD8 BV13S2 YFCAS IPGLAGL NEQF..BJ2S1 BC2 11 
HAM4 CD4 BV24 YLCATS RGGGVG YNEQF..BJ2S1 BC1 12 
 CD8 BV2 YICSA PSGDN NEQF..BJ2S1 BC2 
 CD8 BV4 YLCSV QARIDH NEQF..BJ2S1 BC2 10 
 CD8 BV8 YFCASS LGAGP YEQY..BJ2S7 BC1 10 
HAM5 CD4 BV4 YLCSVE KRGSG TGELF..BJ2S2 BC2 11 
 CD4 BV18 YFCASS PGQG EKLF..BJ1S4 BC1 
 CD4 BV22 YFCAS RTGTQ SYEQY..BJ2S7 BC2 10 
 CD8 BV1 YFCASS PRGTD TEAF..BJ1S1 BC1 10 
 CD8 BV4 YLCS DGRGG YNEQF..BJ2S1 BC1 
 CD8 BV6 YLCASS PGPLD NEQF..BJ2S1 BC2 10 
 CD8 BV8 YFCAS TQGI YNEQF..BJ2S1 BC2 
 CD8 BV13S1 YFCASS PGRGV YNEQF..BJ2S1 BC2 11 
 CD8 BV16 YFCASS QEGEGAQ EKLF..BJ1S4 BC2 12 
 CD8 BV19 YLCASS QSTGQGTSP YEQY..BJ2S7 BC2 14 
 CD8 BV20 YLCAWS AATYMGDT EAF..BJ1S1 BC1 12 
IndividualSubpopulationBVBV EndN-D-NBJBCCDR3 length
HAM1 CD4 BV13S2 YFCASS SRPG GANVLT..BJ2S6 BC2 11 
 CD8 BV4 YLCSV TGASSGD EQF..BJ2S1 BC1 10 
 CD8 BV9 YFCASS SGPLEGS YEQY..BJ2S7 BC2 12 
 CD8 BV5S1 YLCASS LVPG SYNEQF..BJ2S1 BC2 11 
 CD8 BV13S1 YFCASS CPGQGV ETQY..BJ2S5 BC2 11 
 CD8 BV19 YLCASS RPTGTGAN EQY..BJ2S7 BC2 12 
 CD8 BV21 YLCASS PELGQF NEQF..BJ2S1 BC2 11 
 CD8 BV24 YLCAT RDRGRG NEQF..BJ2S1 BC2 10 
HAM2 CD4 BV8 YFCASS SPHRGV NEQF.BJ2S1 BC1 11 
 CD8 BV2 YICS TRGWGRRS YEQY..BJ2S7 BC2 11 
 CD8 BV11 YLCAS ARQL YNEQF..BJ2S1 BC2 
 CD8 BV12 YFCA ISYSGEG YEQY..BJ2S7 BC2 10 
 CD8 BV13S2 YFCAS RRGGRG EQF..BJ2S1 BC2 
 CD8 BV14 YFCASS LVG STDTQY..BJ2S3 BC1 10 
 CD8 BV18 YFCASS PDREI DTQY..BJ2S3 BC2 10 
 CD8 BV20 YLCAWS GPSCLG EKLF..BJ1S4 BC1 11 
 CD8 BV24 YLCATS RIAG ETQY..BJ2S5 BC2 
HAM3 CD8 BV5S1 YLCAS RMDRGY YNEQF..BJ2S1 BC2 11 
 CD8 BV11 YLCASS QRGGE ETQY..BJ2S5 BC2 10 
 CD8 BV13S2 YFCAS IPGLAGL NEQF..BJ2S1 BC2 11 
HAM4 CD4 BV24 YLCATS RGGGVG YNEQF..BJ2S1 BC1 12 
 CD8 BV2 YICSA PSGDN NEQF..BJ2S1 BC2 
 CD8 BV4 YLCSV QARIDH NEQF..BJ2S1 BC2 10 
 CD8 BV8 YFCASS LGAGP YEQY..BJ2S7 BC1 10 
HAM5 CD4 BV4 YLCSVE KRGSG TGELF..BJ2S2 BC2 11 
 CD4 BV18 YFCASS PGQG EKLF..BJ1S4 BC1 
 CD4 BV22 YFCAS RTGTQ SYEQY..BJ2S7 BC2 10 
 CD8 BV1 YFCASS PRGTD TEAF..BJ1S1 BC1 10 
 CD8 BV4 YLCS DGRGG YNEQF..BJ2S1 BC1 
 CD8 BV6 YLCASS PGPLD NEQF..BJ2S1 BC2 10 
 CD8 BV8 YFCAS TQGI YNEQF..BJ2S1 BC2 
 CD8 BV13S1 YFCASS PGRGV YNEQF..BJ2S1 BC2 11 
 CD8 BV16 YFCASS QEGEGAQ EKLF..BJ1S4 BC2 12 
 CD8 BV19 YLCASS QSTGQGTSP YEQY..BJ2S7 BC2 14 
 CD8 BV20 YLCAWS AATYMGDT EAF..BJ1S1 BC1 12 
Table VI.

Predicted amino acid sequence of the CDR3 region of TCR BV-chains in a patient with ATL (ATL1)

IndividualSubpopulationBVBV EndN-D-NBJBCCDR3 Length
ATL1 CD4 BV7 YLCSSS QEDRV SPLH..BJ1S6 BC1 10 
 CD8 BV5S2 YLCASS SDSHAY GYT..BJ1S2 BC1 10 
 CD8 BV9 YFCASS QVVH EQY..BJ2S7 BC2 
 CD8 BV10 YFCAS TTLGGQKRP GELF..BJ2S2 BC2 13 
 CD8 BV11 YLCASS PASGGVY DEQF..BJ2S1 BC2 12 
 CD8 BV17 YLCASS IQGFA YNEQF..BJ2S1 BC2 11 
 CD8 BV20 YLCAWS PATGN YEQY..BJ2S7 BC2 10 
 CD8 BV22 YFCASS DQG YNEQF..BJ2S1 BC2 
 CD8 BV24 YLCATS SVAG ETQY..BJ2S5 BC2 
IndividualSubpopulationBVBV EndN-D-NBJBCCDR3 Length
ATL1 CD4 BV7 YLCSSS QEDRV SPLH..BJ1S6 BC1 10 
 CD8 BV5S2 YLCASS SDSHAY GYT..BJ1S2 BC1 10 
 CD8 BV9 YFCASS QVVH EQY..BJ2S7 BC2 
 CD8 BV10 YFCAS TTLGGQKRP GELF..BJ2S2 BC2 13 
 CD8 BV11 YLCASS PASGGVY DEQF..BJ2S1 BC2 12 
 CD8 BV17 YLCASS IQGFA YNEQF..BJ2S1 BC2 11 
 CD8 BV20 YLCAWS PATGN YEQY..BJ2S7 BC2 10 
 CD8 BV22 YFCASS DQG YNEQF..BJ2S1 BC2 
 CD8 BV24 YLCATS SVAG ETQY..BJ2S5 BC2 
1

This work was supported by the Japanese Foundation for AIDS Prevention (W.W.H.) and by National Institutes of Health Grants CA 64038 (W.W.H.) and AI33454 (P.K.G.). P.K.G. is indebted to Mr. and Mrs. James C. Dudley and the Guildford Fund for additional research support.

3

Abbreviations used in this paper: HTLV, human T cell lymphotropic virus; AC, asymptomatic carrier; ATL, adult T cell leukemia; HAM/TSP, HTLV-I-associated myelopathy/tropical spastic paraparesis; SSCP, single-strand conformation polymorphism; HLA, human leukocyte Ag; CDR, complementarity-determining region.

1
Takatsuki, K., K. Yamaguchi, M. Matsuoka.
1996
. Adult T-cell leukemia. P. Höllsberg, and D. A. Hafler, eds.
Human T-Cell Lymphotropic Virus Type I
219
Wiley & Sons, Chichester, U.K.
2
Osame, M., J. C. McArthur.
1992
. Neurologic manifestations of infection with human T cell lymphotropic virus type I. A.K. Asbury, and G. M. McKhann, and W. I. McDonald, eds.
Diseases of the Nervous System: Clinical Neurobiology II
1331
Saunders, Philadelphia.
3
Höllsberg, P., D. A. Hafler.
1993
. Pathogenesis of diseases induced by human lymphotropic virus type I infection.
N. Engl. J. Med.
328
:
1173
4
Ijichi, S., M. Nakagawa, F. Umehara, I. Higuchi, K. Arimura, S. Izumo, M. Osame.
1996
. HAM/TSP: recent perspectives in Japan.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
13
: (Suppl1):
S26
5
Levin, M.C., S. Jacobson.
1997
. HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): a chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system.
J. Neurovirol.
3
:
126
6
Richardson, J. H., A. J. Edwards, J. K. Cruickshank, P. Rudge, A. G. Dalgleish.
1990
. In vivo cellular tropism of human T-cell leukemia virus type 1.
J. Virol.
64
:
5682
7
Newbound, G, J. M. C., J. M. Andrews, J. N. J. .P. O’Rourke, J. N. Brady, M. D Lairmore.
1996
. Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes.
J. Virol.
70
:
2101
8
Osame, M., S. Ijichi.
1993
. Benign monoclonal T cell proliferation in HTLV-I infection.
Med. Hypotheses
41
:
363
9
Wattel, E., J.-P. Vartanian, C. Pannetier, S. Wain-Habson.
1995
. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy.
J. Virol.
69
:
2863
10
Cavrois, M., A. Gessain, S. Wain-Hobson, E. Wattel.
1996
. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM.
Oncogene
1
:
2419
11
Wattel, E., M. Cavrois, A. Gessain, S. Wain-Hobson.
1996
. Clonal expansion of infected cells: a way of life for HTLV-I.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
13
: (Suppl 1):
S92
12
Utz, U., D. Banks, S. Jacobson, W. E. Biddison.
1996
. Analysis of the T-cell receptor repertoire of human T-cell leukemia virus type 1 (HTLV-1) Tax-specific CD8+ cytotoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion.
J. Virol.
70
:
843
13
Höger, T. A., S. Jacobson, T. Kawanishi, T. Kato, K. Nishioka, K. Yamamoto.
1997
. Accumulation of human T lymphotropic virus (HTLV)-I-specific T cell clones in HTLV-I-associated myelopathy/tropical spastic paraparesis patients.
J. Immunol.
159
:
2042
14
Bodmer, J. G., S. G. Marsh, E. D. Albert, W. F. Bodmer, B. Dupont, H. A. Erlich, B. Mach, W. R. Mayr, P. Parham, T. Sasazuki.
1992
. Nomenclature for factors of the HLA system, 1991: WHO Nomenclature Committee for factors of the HLA system.
Tissue Antigens
39
:
161
15
Ota, M., T. Seki, H. Fukushima, K. Tsuji, H. Inoko.
1992
. HLA-DRB1 genotyping by modified PCR-RFLP method combined with group-specific primers.
Tissue Antigens
39
:
187
16
Nomura, N., M. Ota, K. Tsuji, H. Inoko.
1991
. HLA-DQB1 genotyping by modified PCR- RFLP method combined with group-specific primers.
Tissue Antigens
38
:
53
17
Monteiro, J., R. Hingorani, I. H. Choi, J. Silver, R. Pergolizzi, P. K. Gregersen.
1995
. Oligoclonality in the human CD8+ T cell repertoire in normal subjects and monozygotic twins: implications for studies of infectious and autoimmune diseases.
Mol. Med.
1
:
614
18
Hingorani, R., I. H. Choi, P. Alolkar, B. Gulwani-Alolkar, R. Pergolizzi, J. Silver, and P. K. Gregersen. Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects. J. Immunol. 151:5762.
19
Morley, J. K., F. M. Batliwalla, R. Hingorani, P. K. Gregersen.
1995
. Oligoclonal CD8+ T cells are preferentially expanded in the CD57+ subset.
J. Immunol.
154
:
6182
20
Batliwalla, F., J. Monteiro, D. Serrano, P. K. Gregersen.
1996
. Oligoclonality of CD8+ T cells in health and disease: ageing, infection, or immune regulation?.
Hum. Immunol.
48
:
68
21
Hingorani, R., J. Monteiro, R. Furie, E. Chartash, C. Navarrete, R. Pergolizzi, and P. K. Gregersen. Oligoclonality of Vβ 3 TCR chains in the CD8+ T cell population of rheumatoid arthritis patients. J. Immunol. 156:852.
22
Monteiro, J., R. Hingorani, R. Peroglizzi, B. Apatoff, P. K. Gregersen.
1996
. Oligoclonality of CD8+ T cells in multiple sclerosis.
Autoimmunity
23
:
127
23
Jacobson, S., H. Shida, D. E. McFarlin, A. S. Fauci, S. Koenig.
1990
. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.
Nature
348
:
245
24
Kannagi, M., S. Harada, I. Maruyama, H. Inoko, H. Garashi, G. Kuwashima, S. Sato, M. Morita, M. Kidokoro, M. Sugimoto, S. Funahashi, M. Osame, H. Shida.
1991
. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells.
Int. Immunol.
3
:
761
25
Elovaara, I., S. Koenig, A. Y. Brewah, R. M. Woods, T. Lehky, S. Jacobson.
1993
. High human T cell lymphotropic virus type I (HTLV-I)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease.
J. Exp. Med.
177
:
1567
26
Parker, C. E., S. Daenke, S. Nightingale, C. R. M. Bangham.
1992
. Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis.
Virology
188
:
628
27
Daenke, S., A. G. Kermode, S. E. Hall, G. Taylor, J. Weber, S. Nightingale, and C. R. M. Bangham. High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis. Virology 217:139.
28
Elovaara, I., U. Utz, S. Smith, S. Jacobson.
1995
. Limited T cell receptor usage by HTLV-I tax-specific, HLA class I restricted cytotoxic T lymphocytes from patients with HTLV-I associated neurological disease.
J. Neuroimmunol.
63
:
47
29
Hara, H., M. Morita, T. Iwaki, T. Hatae, Y. Itoyama, T. Kitamoto, S. Akizuki, I. Goto, T. Watanabe.
1994
. Detection of human T lymphotropic virus type I (HTLV-I) proviral DNA and analysis of T cell receptor Vβ CDR3 sequences in spinal cord lesions of HTLV-I-associated myelopathy/tropical spastic paraparesis.
J. Exp. Med.
180
:
831
30
Kersh, G. J., P. M. Allen.
1996
. Essential flexibility in the T-cell recognition of antigen.
Nature
380
:
495
31
Rowen, L., B. F. Koop, L. Hood.
1996
. The complete 685-kilobase DNA sequence of the human T cell receptor locus.
Science
272
:
1755
32
Furukawa, Y., J. Fujisawa, M. Osame, M. Toita, S. Sonoda, R. Kubota, S. Ijichi, and M. Yoshida. Frequent clonal proliferation of human T-cell leukemia virus type I (HTLV-I)-infected T cells in HTLV-I-associated myelopathy (HAM-TSP). Blood 80:1012.
33
Moss, P. A.H., J.I. Bell.
1996
. Comparative sequence analysis of the human T cell receptor TCRA and TCRB (CDR3) regions.
Hum. Immunol.
48
:
32
34
Ijichi, S., M. Ramundo, H. Takahashi, W. W. Hall.
1992
. In vivo cellular tropism of Human T cell leukemia virus type II (HTLV-II).
J. Exp. Med.
176
:
293
35
Yoshida, M. M., H. Osame, M. Kawai, N. Toita, Y. Kuwasaki, Y. Nishida, K. Hiraki, K. Takahashi, S. Nomura, N. Sonoda, S. Ijichi Eiraku, K. Usuku.
1989
. Increased replication of HTLV-I in HTLV-I-associated myelopathy.
Ann. Neurol.
26
:
331
36
Nishimura, M., A. Adachi, I. Akiguchi, N. Shirahata, M. Maeda, A. Ishimoto, T. Mezaki, J. Kimura.
1990
. High ratio of HTLV-1-infected cells in HTLV-1 associated myelopathy (HAM).
Acta Neurol. Scand.
81
:
209
37
Gessain, A., F. Saal, O. Gout, M.-T. Daniel, G. Flandrin, G. de The, J. Peries, F. Sigaux.
1990
. High human T-cell lymphotropic virus type I proviral DNA load with polyclonal integration in peripheral blood mononuclear cells of French West Indian, Guianese, and African patients with tropical spastic paraparesis.
Blood
75
:
428
38
Kira, J., Y. Koyanagi, T. Yamada, Y. Itoyama, I. Goto, N. Yamamoto, H. Sasaki, and Y. Sakaki. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. Ann. Neurol. 29:194.
39
Furukawa, Y., M. Osame, R. Kubota, M. Tara, M. Yoshida.
1995
. Human T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells.
Blood
85
:
1865
40
Kamihira, S., H. Kohda, N. Oyakawa, Y. Moriuti, S. Momita, S. Ikeda, Y. Yamada, M. Ichimaru, K. Kinosita, H. Okuda, M. Kanamura, T. Oota.
1989
. Immunoglobulin classes of antibody for human T-lymphotropic virus type-I (HTLV-I) in healthy donors and HTLV-I-associated disorders.
Vox. Sang.
56
:
168
41
Nagasato, K., T. Nakamura, S. Shirabe, K. Shibayama, K. Ohishi, K. Ichinose, M. Tsujihata, S. Nagataki.
1991
. Presence of serum anti-human T-lymphotropic virus type I (HTLV-I) IgM antibodies means persistent active replication of HTLV-I in HTLV-I-associated myelopathy.
J. Neurol. Sci.
103
:
203
42
Usuku, K., S. Sonoda, M. Osame, S. Yashiki, K. Takahashi, M. Matsumoto, T. Sawada, K. Tsuji, M. Tara, A. Igata.
1988
. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma.
Ann. Neurol.
23
: (Suppl):
S143
43
Eiraku, N., S. Ijichi, S. Yashiki, M. Osame, S. Sonoda.
1992
. Cell surface phenotype of in vitro proliferating lymphocytes in HTLV-I-associated myelopathy (HAM/TSP).
J. Neuroimmunol.
37
:
223
44
Ijichi, S., S. Izumo, N. Eiraku, K. Machigashira, R. Kubota, M. Nagai, N. Ikegami, N. Kashio, F. Umehara, I. Maruyama, M. Osame.
1993
. An autoaggressive process against bystander tissues in HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP.
Med. Hypotheses
41
:
542
45
Ijichi, S., K. Machigashira, M. Nagai, M. Osame, W. W. Hall.
1996
. Late phase spontaneous proliferation of cultured peripheral blood lymphocytes associated with HTLV-I infection: involvement of cellular responses against the infected cells.
Jpn. J. Trop. Med. Hyg.
24
:
143
46
Machigashira, K., S. Ijichi, M. Nagai, Y. Yamano, W.W. Hall, M. Osame.
1997
. In vitro virus propagation and high cellular responsiveness to the infected cells in patients with HTLV-I-associated myelopathy (HAM/TSP).
J. Neuroimmunol.
149
:
141
47
Jacobson, S., D. E. McFarlin, S. Robinson, R. Voskuhl, R. Martin, A. Brewah, A. J. Newell, S. Koenig.
1992
. HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease.
Ann. Neurol.
32
:
651
48
Kuroda, Y., H. Takashima.
1990
. Impairment of cell-mediated immune responses in HTLV-I-associated myelopathy.
J. Neurol. Sci.
100
:
211
49
Fujihara, K., Y. Itoyama, F. Yu, C. Kubo, I. Goto.
1991
. Cellular immune surveillance against HTLV-I infected T lymphocytes in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP).
J. Neurol. Sci.
105
:
99
50
Fujihara, K., Y. Itoyama, F. Yu, C. Kubo, I. Goto.
1995
. Antibody-dependent cell-mediated cytotoxicity (ADCC) in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP).
J. Neurol. Sci.
142
:
65
51
Nakagawa, M., K. Nakahara, Y. Maruyama, M. Kawabata, I. Higuchi, H. Kubota, S. Izumo, K. Arimura, M. Osame.
1996
. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
Neurovirology
2
:
345